POSTMENOPAUSAL HORMONE THERAPY AND THE INCIDENCE OF BREAST CANCER
40 YEAR TRENDS IN POSTMENOPAUSAL HORMONE THERAPY AND THE INCIDENCE OF BREAST CANCER - DISPARITIES EXIST BETWEEN BLACK AND WHITE WOMEN
The study out of MD Anderson reporting ‘double the mastectomy rate’ for patients treated with accelerated partial breast irradiation compared to whole breast irradiation, has created a tremendous amount of angst in the lay and medical press. Studies such as these that rely on large retrospective databases can provide interesting data although it all depends on the quality of data entered and how it is extracted.
As co-principle investigator of The American Society of Breast Surgeons (ASBS) Mammosite Registry we have prospectively followed patients and retrospectively analyzed the data. However, we have not seen the same high complication or mastectomy rates as this study reported.
Perhaps the MD Anderson study speaks to patients being cared for by breast cancer specialists with our low complication/recurrence rates.
You Might Also Enjoy...
40 YEAR TRENDS IN POSTMENOPAUSAL HORMONE THERAPY AND THE INCIDENCE OF BREAST CANCER - DISPARITIES EXIST BETWEEN BLACK AND WHITE WOMEN
A study presented at the annual meeting of the American Society of Clinical Oncology and published online by the NEJMindicates Exemestane, which is now used to prevent recurrences of breast cancer, can also reduce the risk of it occurring.
“Before the advent of sentinel node biopsy essentially all women with invasive cancer had to have a complete axillary lymph node dissection…."
The American Joint Commission on Cancer or AJCC has a staging system for all cancers including melanoma.